Hospitals are the largest end‑user segment — they have the infusion suites, the emergency backup, and the multidisciplinary teams. But specialty clinics are the fastest‑growing. The rituximab market research study shows that specialty clinics are growing at over 7% CAGR, driven by the shift to outpatient cancer care and the rise of subcutaneous formulations.

What's the advantage of a specialty clinic? Shorter wait times, more personalized care, and lower costs. The rituximab market trends highlight that the fastest‑growing end‑user segment is home care, as visiting nurses administer SC Rituximab in patients' homes.

But clinics may not have the resources to manage infusion reactions (fever, chills, low blood pressure). That's why the first dose is usually given in a hospital.

The bottom line: for maintenance doses, a specialty clinic or home care is fine. For the first dose, stick with a hospital. Safety first.